PARP, IDO, CAR-T and more: What we’re watching for at #ASCO17 – FiercePharma
FiercePharma |
PARP, IDO, CAR–T and more: What we're watching for at #ASCO17
FiercePharma Nanjing Legend Biotech is looking to set out a new-type of CAR–T cell therapy in relapsed/refractory multiple myeloma for LCAR-B38M in an early-to-midstage trial. Its ongoing trial is primarily set up to assess any treatment-related AEs, but secondary … |
